by Clinical Neuropsychologist | Thursday, January 30, 2025 | Dementia
Abstract INTRODUCTION The phase 3 trial CLARITY AD found lecanemab slowed cognitive decline by 27%. However, subgroup analyses indicated a significant 31% sex difference in the effect and suggested no or limited effectiveness in females. We used simulations...
by Clinical Neuropsychologist | Wednesday, January 29, 2025 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | January 29, 2025 Wiley: Alzheimer’s & Dementia:...
by Clinical Neuropsychologist | Friday, January 24, 2025 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) patients with higher educational attainment (EA) often exhibit better cognitive function. However, the relationship among EA status, AD pathology, structural brain reserve, and cognitive decline requires further...
by Clinical Neuropsychologist | Friday, January 24, 2025 | Dementia
Abstract INTRODUCTION Lewy body dementia (LBD) shares genetic risk factors with Alzheimer’s disease (AD), including apolipoprotein E (APOE), but is distinguishable at the genome-wide level. Polygenic risk scores (PRS) may therefore improve diagnostic...
by Clinical Neuropsychologist | Thursday, January 23, 2025 | Dementia
Abstract INTRODUCTION Hearing impairment is associated with dementia. We aimed to clarify the association between hearing impairment and future cognitive test performance measured by the Montreal Cognitive Assessment Scale (MoCA), adjusted for confounders, avoiding...
